Shipman & Goodwin 
Counselors at Law
Drugs and Medical Devices – A Shipman & Goodwin® Alert
June 14, 2018

Federal “Right to Try Act” Becomes Law: What Your Risk Management Team Needs to Know
Authors and Contributors: Sarah A. Westby, (860) 251-5503, swestby@goodwin.com
Adam M. Masin, (860) 251-5154, amasin@goodwin.com 
	On May 30, 2018, Congress enacted the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (the “Act”). See Pub. L. No. 115-176, § 204, 132 Stat. 1372 (2018).  The Act allows eligible terminally ill patients to access prescription drugs that have passed Phase 1 clinical trials but that the FDA has not yet approved for general use (“investigational drugs”).  Forty states have adopted variations on “Right to Try” laws.  Yet state law protections and immunities offer little comfort to manufacturers, providers, and patients without a federal law counterpart.    
	The new law aims to fill that void.  It provides for broad-based civil tort immunity and prohibits the FDA from using adverse clinical outcomes to delay or deny drug approval.  Though lauded by some as the saving grace for terminally ill patients, and derided by others as a threat to patient safety, one thing is certain: implementing the Act poses legal, ethical, and administrative challenges for pharmaceutical manufacturers and healthcare providers alike.
Key Provisions of the Act
	Under the Act, patients can gain access to eligible investigational drugs if they (1) have “been diagnosed with a life-threatening disease or condition,” (2) have “exhausted [FDA] approved treatment options and [are] unable to participate in a clinical trial,” and (3) provide “written informed consent” to a treating physician. Pub. L. No. 115-176, § 204.  Pharmaceutical manufacturers may choose to provide access to such investigational drugs, but are not required to do so.
	Significantly, the Act insulates drug manufacturers and providers from liability for any claim arising from the provision of an investigational drug to an eligible patient, unless their actions constitute “reckless or willful misconduct, gross negligence, or an intentional tort under any applicable State law.”  In addition, the FDA may not use clinical outcomes to delay or otherwise adversely affect approval of the investigational drug, unless the FDA determines that the use of such clinical outcome is “critical” to determining drug safety.  Id.
	Although these provisions remove many barriers to providing access to investigational drugs from the manufacturer’s standpoint, manufacturers still have an obligation to report “serious adverse events” to the FDA in the form of an annual report. Id.  In addition, the law leaves many important terms undefined, and several open questions remain.  Before permitting eligible patients to access investigational drugs, manufacturers and providers should consider these incentives, risks, and open questions, among others, in their risk-benefit calculus.
Incentives to Providing Access
•	Good will and social capital: Pharmaceutical manufacturers should consider the potential opportunities for good will among providers, patients, and the media that comes with providing access to investigational drugs.
•	Additional in-vivo data: Use of investigational drugs will generate additional data on the safety and efficacy of the drug outside of the clinical trial setting.  This data may inform decisions on drug improvement, dosing, and administration.  In addition, the manufacturer can report positive patient outcomes to the FDA to consider in approving the drug for general use.
•	Early brand visibility and recognition: Providing investigational drugs to patients and healthcare providers may help prime patients, providers, and purchasers to buy the drug before general marketing efforts have begun, generating brand loyalty and a competitive advantage prior to market entry.

Risks to Consider 
•	Tort litigation and preemption of state law: The law does not expressly address preemption of state law tort claims arising from the provision and use of investigational drugs.  This is a significant concern for manufacturers and providers, due to the uncertainty of immunity from litigation in states where there is no concomitant Right to Try law.
•	Written informed consent requirement is vague: The law does not define the term “written informed consent,” leaving manufacturers and providers guessing as to the level of disclosure required.    
•	Bad press and reputational damage: Investigational drug manufacturers and sponsors must report “known serious adverse events” to the FDA on an annual basis, and the FDA may publish the annual report on its website.
Open Questions
•	“Life threatening disease or condition” is broad: The eligible patient population, as defined, may result in confusion and administrative challenges for manufacturers and providers and sweep in unintended patient populations. 
•	Cost and insurance coverage: Providing investigational drugs free or at cost may not be feasible, but market pricing could deny access to all but the wealthiest patients. In addition, the law provides no guidance on insurance coverage.
•	Physician oversight and input regarding use of investigational drugs: The law is silent on dosing, administration, and monitoring requirements for investigational drugs, leaving providers exposed and without guidance.
•	Providers’ obligation to report adverse events: The law addresses reporting requirements for manufacturers and sponsors of investigational drugs, but it is unclear whether healthcare providers have any federal reporting obligations.
Conclusion
	Pharmaceutical manufacturers and healthcare providers need to consider the ambiguities in the law and anticipate the ways in which they can materialize into real risks for the business and professionals before providing access to investigational drugs.  Well-organized administration and thorough record keeping, as well as robust informed consent protocols will help the manufacturer or provider minimize the risks of increased use of investigational drugs, while capturing the benefits to the business and fulfilling the ultimate goal of expanding patients’ access to life-saving treatment.
Questions or Information
If you have any questions about this alert, please contact Sarah A. Westby at swestby@goodwin.com or Adam M. Masin at amasin@goodwin.com
These materials have been prepared by Shipman & Goodwin LLP for informational purposes only.  They are not intended as advertising and should not be considered legal advice. This information is not intended to create, and receipt of it does not create, a lawyer-client relationship. Viewers should not act upon this information without seeking professional counsel. © 2018 Shipman & Goodwin LLP.
289 Greenwich Avenue
Greenwich, CT  06830-6595
203-869-5600 

One Constitution Plaza
Hartford, CT  06103-1919
860-251-5000

265 Church Street - Suite 1207
New Haven, CT  06510-7013
203-836-2801

400 Park Avenue - Fifth Floor
New York, NY  10022-4406
212-376-3010

300 Atlantic Street
Stamford, CT  06901-3522
203-324-8100

1875 K St., NW - Suite 600
Washington, DC  20006-1251 
202-469-7750

www.shipmangoodwin.com